Xbrane Biopharma AB
Xbrane Biopharma AB, a pioneering biotechnology company headquartered in Sweden, focuses on the development of innovative biosimilars and biologics. Founded in 2006, Xbrane has made significant strides in the biopharmaceutical industry, particularly in the fields of ophthalmology and oncology. The company is renowned for its flagship product, Xlucane, a biosimilar to Lucentis, which addresses serious eye diseases and showcases Xbrane's commitment to enhancing patient care through affordable treatment options. With a strong presence in Europe and expanding operations globally, Xbrane Biopharma has established itself as a key player in the biosimilar market, recognised for its rigorous development processes and high-quality standards. As Xbrane continues to advance its pipeline, it remains dedicated to delivering innovative solutions that meet the evolving needs of healthcare providers and patients alike.
DitchCarbon Score
How does Xbrane Biopharma AB's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Education Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Xbrane Biopharma AB's score of 37 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Xbrane Biopharma AB's reported carbon emissions
In 2023, Xbrane Biopharma AB reported total emissions of approximately 9,000 kg CO2e, with 8,000 kg CO2e attributed to Scope 2 emissions. This marks a reduction from 2022, when the company recorded 10,000 kg CO2e in Scope 2 emissions alone, indicating a positive trend in their emissions management. Xbrane has set ambitious climate commitments, aiming to reduce its Scope 1 emissions to near zero by 2025. Additionally, the company plans to cut its Scope 2 emissions by 50% from a 2020 baseline by 2030, with a target to achieve near-zero Scope 2 emissions by 2025. These initiatives reflect Xbrane's commitment to sustainability and its proactive approach to addressing climate change within the biopharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | - | - |
| Scope 2 | 10,000 | 0,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Xbrane Biopharma AB is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
